Dermapharm Holding Se · XETR:DMP

Dermapharm — Investor Day (2022)

15 slides from Dermapharm's investor day presentation, 2022

  1. Slide 1: Financials – Christof Dreibholz, CFO

    5 Financials – Christof Dreibholz, CFO 1

  2. Slide 2: 5.1 Financial figures 9M 2022

    5.1 Financial figures 9M 2022

  3. Slide 3: Dermapharm Group

    Dermapharm Group Growth impulses from vaccine production and latest M&A deals Total Revenue EBITDA1 Significant revenue growth of 9.6% to €m €m, adjusted €734.3m, due to +9.6% 34.0% YoY  vaccine production in cooperation with EBITDA BioNTech SE 734.3 Margin 32.6%  revenue contribution of acquisiti

  4. Slide 4: Dermapharm Group from revenue to EBITDA

    Dermapharm Group from revenue to EBITDA P&L and adj. EBITDA margin bridge €m and % 34.0% -0.3 pp -1.2 pp -0.5 pp 0.9 pp -0.2 pp 32.6% Adjusted EBITDA margin slightly declined by 22.1 1.4 pp -279.8  Cost of materials: Increase largely in line with 734.3 9M 2022 revenue, negative impact on adj. EBITD

  5. Slide 5: Successful execution of organic and inorganic growth strategy, both in terms of revenue and margin expansion

    Successful execution of organic and inorganic growth strategy, both in terms of revenue and margin expansion since the IPO in Feb 2018 Trommsdorff Allergopharma CAGR1 >€1bn EBITDA +11 pp +18 pp Margin +6.9% +1.3% Revenue +4.9% €467.1m +4.3% +3.4% 2017 2018 2019 2020 2021 FC 2022 Dermapharm Group 1 S

  6. Slide 6: Branded pharmaceuticals and other healthcare products

    Branded pharmaceuticals and other healthcare products Continuous growth in existing portfolio Revenue EBITDA1 Revenue growth of 7.8% to €474.5m, due €m +7.8% €m, adjusted to YoY 48.8% 474.5  strong contribution from vitamins/minerals EBITDA and the Trommsdorff portfolio (Keltican and 440.1 Margin 4

  7. Slide 7: Herbal extracts

    Herbal extracts Growth impulses from latest M&A deals Revenue EBITDA1 Revenue growth of 35.9% to €74.2m, due €m €m, adjusted +35.9% to YoY 28.9% 74.2  increasing sales from Euromed’s extract EBITDA business 54.6 Margin 22.9%  ongoing integration of Cernelle and C3 Group +7.6% YoY 17.0 EBITDA incre

  8. Slide 8: Parallel import business

    Parallel import business Recovery of market and improved profitability Revenue EBITDA Revenue increased by 5.8% to €185.5m, €m €m +5.8% due to YoY 185.5  returning growth in PI market 2.2% 175.4  continuous growth in OTC, narcotics and EBITDA medical cannabis products Margin 1.3%  lower mandatory

  9. Slide 9: Earnings before tax (Group EBT)

    Earnings before tax (Group EBT) Decrease as a result of the impairment of goodwill attributable to Fitvia Group Earnings before tax (EBT)1 EBT decreased by 16.7% to €159.5m €m (unadjusted) resulting in a margin of 21.7%, 28.6% mainly influenced by EBT Margin  Notably higher depreciation and 21.7% -

  10. Slide 10: Cash flows and cash conversion

    Cash flows and cash conversion Dedication to future growth Cash flow and cash conversion1  CF from operating activities favorably €m and in % of Group EBITDA impacted by a slower build-up of 67.8% inventories in 9M 2022 Cash 63.2% conversion  CF from investing activities reflects  Acquisition of

  11. Slide 11: Balance Sheet of Dermapharm Group

    Balance Sheet of Dermapharm Group Balance sheet as of September 30th 2022  Total assets slightly increased to €m €1,451m (31 December 2021: €1,407m)  Non-current assets remain largely unchanged at €908m 1,451 1,451 (31 December 2021: €888m)  Current assets increased to €543m Non-current Equity (3

  12. Slide 12: 5.2 Outlook 2022

    1 ia - ii s o> 5.2 Outlook 2022 T>- Clif. IT

  13. Slide 13: Outlook 2022: Growth strategy on track – confirming guidance 2022

    Outlook 2022 Growth strategy on track – confirming guidance 2022  Growth rates are based on organic growth supported by new launches of in-house developments.  Guidance for the FY 2022 also includes growth impulses from M&A deals and the Growth $ existing cooperation with BioNTech strategy regardi

  14. Slide 14: Disclaimer

    Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward-Looking Stat

  15. Slide 15: For information, please contact

    For information, please contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233 Dermapharm FY 2021 15

Dermapharm Holding — Investor Day (2022) on 6ix